Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
In BriefThis Month in JNM

This Month in JNM

Journal of Nuclear Medicine August 2018, 59 (8) 8A;
  • Article
  • Info & Metrics
  • PDF
Loading

PSMA salivary gland toxicity: Langbein and colleagues look at xerostomia and related side effects of radiolabeled prostate-specific membrane antigen therapies and at the potential for avoiding, mitigating, or reversing these toxicities.

Page 1172

The immunoimaging toolbox: Mayer and Gambhir provide a comprehensive overview of current state-of-the-art immunoimaging, with a focus on imaging strategies and their applications in immunotherapy.

Page 1174

Controversies in radioiodine use: Pryma offers perspective on the challenges of over- and undertreatment with 131I in differentiated thyroid cancer and previews 2 related articles in this issue of JNM.

Page 1184

Thyroid cancer management: Tuttle examines 3 issues in thyroid cancer management: the option of thyroid lobectomy as initial therapy, preoperative neck imaging to optimize initial surgery, and use of 131I for remnant ablation, adjuvant treatment, or known persistent/recurrent disease.

Page 1187

In favor of radioiodine therapy: Schmidt and colleagues review differing opinions about 131I therapy in differentiated thyroid carcinoma and look at research and consensus guidelines that should be considered in treatment decisions for low- and intermediate-risk patients.

Page 1195

Photoacoustic molecular imaging: Yu and colleagues describe the current state of the art in photoacoustic molecular probes, recent translational efforts, and critical barriers to clinical translation of this novel technology.

Page 1202

18F-AlF–labeled biomolecule conjugates: Kumar surveys the development of 18F-AlF labeling as a novel, fast, simple, and inexpensive procedure and points to the need for target-specific biomolecules with demonstrated long-term in vitro and in vivo stability.

Page 1208

18F-FES PET/CT: Kurland and Oesterreich review the role of 18F-fluoroestradiol PET/CT in selecting and managing patients with metastatic breast cancer and in developing new therapies and call for more specific definitions of estrogen receptor heterogeneity.

Page 1210

Heterogeneous 18F-FES uptake in breast cancer: Nienhuis and colleagues analyze 18F-fluoroestradiol PET to assess estrogen receptor expression heterogeneity in tumor and normal tissue at multiple sites in patients with metastatic breast cancer.

Page 1212

89Zr-anti-CD20 mAb theranostics: Yoon and colleagues use PET/CT to assess tumor targeting with 2 89Zr-labeled anti-CD20 monoclonal antibodies and determine their biodistributions in a preclinical mouse model with CD20 xenografts.

Page 1219

PARP-1 radiotherapy in glioblastoma: Jannetti and colleagues demonstrate in mouse studies the potential for 131I- poly(ADP-ribose) polymerase 1 therapeutics to induce DNA damage and apoptosis in cancer cells while sparing healthy brain tissue.

Page 1225

Anti–Müllerian-inhibiting substance receptor type II antibody: Deshayes and colleagues assess in preclinical models the possibility of using the radiolabeled 16F12 mouse monoclonal antibody in a theranostic approach for small-volume ovarian peritoneal carcinomatosis, such as after cytoreductive surgery.

Page 1234

Measuring BAT activity with radiometry: Crandall and colleagues evaluate in healthy human subjects the operating characteristics of a microwave radiometry system in noninvasive assessment of activated and nonactivated brown adipose tissue to reflect metabolic activity.

Page 1243

β-cell mass imaging with 11C-(+)-PHNO: Bini and colleagues evaluate PET brain radioligands in the pancreas in healthy controls and type-1 diabetes mellitus subjects and identify this D3-preferring receptor agonist as a potential marker of β-cell mass.

Page 1249

PE in sickle cell disease: Tivnan and colleagues explore the influence of chest radiography in patient selection and diagnostic performance of CT pulmonary angiography or ventilation–perfusion scintigraphy in suspected pulmonary emboli in sickle cell disease.

Page 1255

18F-GE180 versus 11C-PBR28: Zanotti-Fregonara and colleagues compare 18F-GE180, a third-generation PET tracer for quantifying the translocator protein (TSPO), and the well-established TSPO tracer 11C-PBR28 by scanning with each tracer during the same day in the same subjects.

Page 1260

Quantification of 18F-PBR111 binding: Ottoy and colleagues determine whether the test–retest variability of 18F-PBR111, a second-generation PET ligand that specifically binds to the translocator protein, is acceptable to detect a psychosis-associated neuroinflammatory signal in schizophrenia.

Page 1267

Dosimetry of 18F-FE-PE2I: Lizana and colleagues investigate the whole-body biodistribution and dosimetry of this radioligand in healthy volunteers to determine its utility as a suitable PET imaging agent for the dopamine transporter.

Page 1275

Dosimetry with updated ICRP phantoms: Josefsson and colleagues use 68Ga-DOTATATE PET/CT scans to compare dosimetry based on the most recent International Commission on Radiological Protection standards (phantoms and tissue-weighting factors) with dosimetry based on prior standards.

Page 1281

Body-surface-area model limitations: Kafrouni and colleagues quantitatively assess the ability of the body-surface-area model to predict tumor-absorbed dose and treatment outcome with 90Y microspheres through retrospective voxel-based dosimetry.

Page 1289

Comparing multimeric 68Ga-RGD peptides: Lobeek and colleagues compare the targeting characteristics of 4 68Ga-labeled multimeric cyclic arginine-glycine-aspartate–based tracers in an αvβ3 integrin–expressing tumor model and a model in which αvβ3 integrin is expressed solely on the neovasculature.

Page 1296

18F-FDG PET in the octopus: Zullo and colleagues report on a method of administering 18F-FDG to the common octopus to perform a PET biodistribution assay characterizing glucose metabolism in organs and regenerating tissues.

Page 1302

Imaging liver injury with 18F-DFA PET: Salas and colleagues evaluate in a preclinical model whether 18F-2-deoxy-2-fluoroarabinose, a PET radiotracer that measures the ribose salvage pathway, can be used to monitor acetaminophen-induced liver injury and failure.

Page 1308

Fluorescence imaging of rucaparib: Kossatz and colleagues describe the intrinsic fluorescence properties of the clinically approved poly(ADP-ribose)polymerase inhibitor rucaparib and its potential to directly measure drug distribution and target engagement.

Page 1316

Harmonization for multicenter PET studies: Orlhac and colleagues propose a method that, by removing the center effect while preserving patient-specific effects, standardizes features measured from PET images obtained using different imaging protocols.

Page 1321

PET/MR measurement of CBF: Ssali and colleagues detail a noninvasive PET/MR imaging approach to cerebral blood flow quantification in 15O-water PET that eliminates the need to measure arterial input function.

Page 1329

  • © 2018 by the Society of Nuclear Medicine and Molecular Imaging.
PreviousNext
Back to top

In this issue

Journal of Nuclear Medicine: 59 (8)
Journal of Nuclear Medicine
Vol. 59, Issue 8
August 1, 2018
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
This Month in JNM
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
This Month in JNM
Journal of Nuclear Medicine Aug 2018, 59 (8) 8A;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
This Month in JNM
Journal of Nuclear Medicine Aug 2018, 59 (8) 8A;
Twitter logo Facebook logo LinkedIn logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Info & Metrics
  • PDF

Related Articles

  • A Postreconstruction Harmonization Method for Multicenter Radiomic Studies in PET
  • PARP-1–Targeted Radiotherapy in Mouse Models of Glioblastoma
  • 18F-PBR111 PET Imaging in Healthy Controls and Schizophrenia: Test–Retest Reproducibility and Quantification of Neuroinflammation
  • Heterogeneity in Metastatic Breast Cancer 18F-Fluoroestradiol Uptake: Clinically Actionable, Biologically Illuminating?
  • Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer
  • A Noninvasive Method for Quantifying Cerebral Blood Flow by Hybrid PET/MRI
  • Small-Animal 18F-FDG PET for Research on Octopus vulgaris: Applications and Future Directions in Invertebrate Neuroscience and Tissue Regeneration
  • Controversial Issues in Thyroid Cancer Management
  • Comparative Dosimetry for 68Ga-DOTATATE: Impact of Using Updated ICRP Phantoms, S Values, and Tissue-Weighting Factors
  • Recent Development of Technology and Application of Photoacoustic Molecular Imaging Toward Clinical Translation
  • 18F-AlF–Labeled Biomolecule Conjugates as Imaging Pharmaceuticals
  • Noninvasive Imaging of Drug-Induced Liver Injury with 18F-DFA PET
  • A Matter of Controversy: Is Radioiodine Therapy Favorable in Differentiated Thyroid Carcinoma?
  • The Immunoimaging Toolbox
  • In Vivo Characterization of 4 68Ga-Labeled Multimeric RGD Peptides to Image αvβ3 Integrin Expression in 2 Human Tumor Xenograft Mouse Models
  • Imaging for Pulmonary Embolism in Sickle Cell Disease: A 17-Year Experience
  • Salivary Gland Toxicity of PSMA Radioligand Therapy: Relevance and Preventive Strategies
  • Head-to-Head Comparison of 11C-PBR28 and 18F-GE180 for Quantification of the Translocator Protein in the Human Brain
  • Evaluation of Next-Generation Anti-CD20 Antibodies Labeled with 89Zr in Human Lymphoma Xenografts
  • Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
  • Measurement of Brown Adipose Tissue Activity Using Microwave Radiometry and 18F-FDG PET/CT
  • Evaluation of PET Brain Radioligands for Imaging Pancreatic β-Cell Mass: Potential Utility of 11C-(+)-PHNO
  • 18F-Fluoroestradiol Tumor Uptake Is Heterogeneous and Influenced by Site of Metastasis in Breast Cancer Patients
  • Controversies on the Use of Radioiodine in Thyroid Cancer: We Need More and Better Data
  • Direct Imaging of Drug Distribution and Target Engagement of the PARP Inhibitor Rucaparib
  • Retrospective Voxel-Based Dosimetry for Assessing the Ability of the Body-Surface-Area Model to Predict Delivered Dose and Radioembolization Outcome
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • This Month in JNM
  • This Month in JNM
  • This Month in JNM
Show more This Month in JNM

Similar Articles

SNMMI

© 2023 Journal of Nuclear Medicine

Powered by HighWire